Intravenous immunoglobulin for suspected or proven infection in neonates.
CONCLUSIONS: The undisputable results of the INIS trial, which enrolled 3493 infants, and our meta-analyses (n = 3973) showed no reduction in mortality during hospital stay, or death or major disability at two years of age in infants with suspected or proven infection. Although based on a small sample size (n = 266), this update provides additional evidence that IgM-enriched IVIG does not significantly reduce mortality during hospital stay in infants with suspected infection. Routine administration of IVIG or IgM-enriched IVIG to prevent mortality in infants with suspected or proven neonatal infection is not recommended. No further research is recommended.
PMID: 31995649 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Ohlsson A, Lacy JB Tags: Cochrane Database Syst Rev Source Type: research
More News: Databases & Libraries | Disability | Fungal Infections | General Medicine | Perinatology & Neonatology | Science | Statistics | Study